 | • レポートコード：GIR201105762 • 出版社/出版日：GlobalInfoResearch / 2020年10月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール • 産業分類：医薬品・医療 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、神経内分泌腫瘍（NET）治療の世界市場を調査対象にし、神経内分泌腫瘍（NET）治療の市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（ソマトスタチン類似体（SSA）、標的療法、その他）、用途別分析（病院、クリニック、その他）、市場予測（2021年～2025年）、販売チャンネル・代理店分析情報などを整理しました。 ・市場概要 ・メーカー情報：Advanced Accelerator Applications、Progenics Pharmaceuticals、Hutchison MediPharma Limited、AVEO Oncology、Pfizer, Inc、Boehringer Ingelheim International、Novartis AG、IpsenPharma ・メーカー別販売量、売上、市場シェア ・神経内分泌腫瘍（NET）治療の地域別市場分析 ・神経内分泌腫瘍（NET）治療の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・神経内分泌腫瘍（NET）治療のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・神経内分泌腫瘍（NET）治療のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・神経内分泌腫瘍（NET）治療の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・神経内分泌腫瘍（NET）治療の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・神経内分泌腫瘍（NET）治療の種類別市場規模2015-2020：ソマトスタチン類似体（SSA）、標的療法、その他 ・神経内分泌腫瘍（NET）治療の用途別市場規模2015-2020：病院、クリニック、その他 ・神経内分泌腫瘍（NET）治療の世界市場予測2021-2025：地域別、種類別、用途別 ・販売チャンネル・代理店分析 ・調査の結果・結論 |
Market Overview
The global Neuroendocrine Tumors (NETs) Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Neuroendocrine Tumors (NETs) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Neuroendocrine Tumors (NETs) Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Neuroendocrine Tumors (NETs) Treatment market has been segmented into
Somatostatin Analogs (SSAs)
Targeted Therapy
Other
By Application, Neuroendocrine Tumors (NETs) Treatment has been segmented into:
Hospitals
Clinics
Other
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Neuroendocrine Tumors (NETs) Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Neuroendocrine Tumors (NETs) Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Neuroendocrine Tumors (NETs) Treatment market.
The report offers in-depth assessment of the growth and other aspects of the Neuroendocrine Tumors (NETs) Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Neuroendocrine Tumors (NETs) Treatment Market Share Analysis
Neuroendocrine Tumors (NETs) Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Neuroendocrine Tumors (NETs) Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Neuroendocrine Tumors (NETs) Treatment sales, revenue and market share for each player covered in this report.
The major players covered in Neuroendocrine Tumors (NETs) Treatment are:
Advanced Accelerator Applications
Progenics Pharmaceuticals
Hutchison MediPharma Limited
AVEO Oncology
Pfizer, Inc
Boehringer Ingelheim International
Novartis AG
IpsenPharma
Among other players domestic and global, Neuroendocrine Tumors (NETs) Treatment market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neuroendocrine Tumors (NETs) Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neuroendocrine Tumors (NETs) Treatment, with price, sales, revenue and global market share of Neuroendocrine Tumors (NETs) Treatment in 2018 and 2019.
Chapter 3, the Neuroendocrine Tumors (NETs) Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuroendocrine Tumors (NETs) Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Neuroendocrine Tumors (NETs) Treatment market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Neuroendocrine Tumors (NETs) Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Neuroendocrine Tumors (NETs) Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Somatostatin Analogs (SSAs)
1.2.3 Targeted Therapy
1.2.4 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Overview of Global Neuroendocrine Tumors (NETs) Treatment Market
1.4.1 Global Neuroendocrine Tumors (NETs) Treatment Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Advanced Accelerator Applications
2.1.1 Advanced Accelerator Applications Details
2.1.2 Advanced Accelerator Applications Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Advanced Accelerator Applications SWOT Analysis
2.1.4 Advanced Accelerator Applications Product and Services
2.1.5 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Progenics Pharmaceuticals
2.2.1 Progenics Pharmaceuticals Details
2.2.2 Progenics Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Progenics Pharmaceuticals SWOT Analysis
2.2.4 Progenics Pharmaceuticals Product and Services
2.2.5 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Hutchison MediPharma Limited
2.3.1 Hutchison MediPharma Limited Details
2.3.2 Hutchison MediPharma Limited Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Hutchison MediPharma Limited SWOT Analysis
2.3.4 Hutchison MediPharma Limited Product and Services
2.3.5 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 AVEO Oncology
2.4.1 AVEO Oncology Details
2.4.2 AVEO Oncology Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 AVEO Oncology SWOT Analysis
2.4.4 AVEO Oncology Product and Services
2.4.5 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Pfizer, Inc
2.5.1 Pfizer, Inc Details
2.5.2 Pfizer, Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Pfizer, Inc SWOT Analysis
2.5.4 Pfizer, Inc Product and Services
2.5.5 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Boehringer Ingelheim International
2.6.1 Boehringer Ingelheim International Details
2.6.2 Boehringer Ingelheim International Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Boehringer Ingelheim International SWOT Analysis
2.6.4 Boehringer Ingelheim International Product and Services
2.6.5 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Novartis AG
2.7.1 Novartis AG Details
2.7.2 Novartis AG Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Novartis AG SWOT Analysis
2.7.4 Novartis AG Product and Services
2.7.5 Novartis AG Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 IpsenPharma
2.8.1 IpsenPharma Details
2.8.2 IpsenPharma Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 IpsenPharma SWOT Analysis
2.8.4 IpsenPharma Product and Services
2.8.5 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Neuroendocrine Tumors (NETs) Treatment Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Neuroendocrine Tumors (NETs) Treatment Manufacturer Market Share in 2019
3.3.2 Top 6 Neuroendocrine Tumors (NETs) Treatment Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Market Share by Regions
4.1.1 Global Neuroendocrine Tumors (NETs) Treatment Sales and Market Share by Regions (2015-2020)
4.1.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue and Market Share by Regions (2015-2020)
4.2 North America Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
4.3 Europe Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
4.5 South America Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Market Share by Country
5.1.1 North America Neuroendocrine Tumors (NETs) Treatment Sales and Market Share by Country (2015-2020)
5.1.2 North America Neuroendocrine Tumors (NETs) Treatment Revenue and Market Share by Country (2015-2020)
5.2 United States Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
5.3 Canada Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
5.4 Mexico Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Market Share by Country
6.1.1 Europe Neuroendocrine Tumors (NETs) Treatment Sales and Market Share by Country (2015-2020)
6.1.2 Europe Neuroendocrine Tumors (NETs) Treatment Revenue and Market Share by Country (2015-2020)
6.2 Germany Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
6.3 UK Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
6.4 France Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
6.5 Russia Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
6.6 Italy Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Revenue and Market Share by Regions (2015-2020)
7.2 China Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
7.3 Japan Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
7.4 Korea Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
7.5 India Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
7.7 Australia Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Market Share by Country
8.1.1 South America Neuroendocrine Tumors (NETs) Treatment Sales and Market Share by Country (2015-2020)
8.1.2 South America Neuroendocrine Tumors (NETs) Treatment Revenue and Market Share by Country (2015-2020)
8.2 Brazil Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
8.3 Argentina Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
9.3 Turkey Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
9.4 Egypt Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
9.5 South Africa Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Neuroendocrine Tumors (NETs) Treatment Sales and Market Share by Type (2015-2020)
10.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue and Market Share by Type (2015-2020)
10.3 Global Neuroendocrine Tumors (NETs) Treatment Price by Type (2015-2020)
11 Global Neuroendocrine Tumors (NETs) Treatment Market Segment by Application
11.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application (2015-2020)
11.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Application (2015-2020)
11.3 Global Neuroendocrine Tumors (NETs) Treatment Price by Application (2015-2020)
12 Market Forecast
12.1 Global Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Growth Rate (2021-2025)
12.2 Neuroendocrine Tumors (NETs) Treatment Market Forecast by Regions (2021-2025)
12.2.1 North America Neuroendocrine Tumors (NETs) Treatment Market Forecast (2021-2025)
12.2.2 Europe Neuroendocrine Tumors (NETs) Treatment Market Forecast (2021-2025)
12.2.3 Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Market Forecast (2021-2025)
12.2.4 South America Neuroendocrine Tumors (NETs) Treatment Market Forecast (2021-2025)
12.2.5 Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Market Forecast (2021-2025)
12.3 Neuroendocrine Tumors (NETs) Treatment Market Forecast by Type (2021-2025)
12.3.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Forecast by Type (2021-2025)
12.3.2 Global Neuroendocrine Tumors (NETs) Treatment Market Share Forecast by Type (2021-2025)
12.4 Neuroendocrine Tumors (NETs) Treatment Market Forecast by Application (2021-2025)
12.4.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Forecast by Application (2021-2025)
12.4.2 Global Neuroendocrine Tumors (NETs) Treatment Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Neuroendocrine Tumors (NETs) Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Neuroendocrine Tumors (NETs) Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Neuroendocrine Tumors (NETs) Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Advanced Accelerator Applications Basic Information, Manufacturing Base and Competitors
Table 8. Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Major Business
Table 9. Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Total Revenue (USD Million) (2018-2019)
Table 10. Advanced Accelerator Applications SWOT Analysis
Table 11. Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Product and Services
Table 12. Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Progenics Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 14. Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Major Business
Table 15. Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Total Revenue (USD Million) (2018-2019)
Table 16. Progenics Pharmaceuticals SWOT Analysis
Table 17. Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Product and Services
Table 18. Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Hutchison MediPharma Limited Basic Information, Manufacturing Base and Competitors
Table 20. Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Major Business
Table 21. Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Total Revenue (USD Million) (2018-2019)
Table 22. Hutchison MediPharma Limited SWOT Analysis
Table 23. Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Product and Services
Table 24. Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. AVEO Oncology Basic Information, Manufacturing Base and Competitors
Table 26. AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Major Business
Table 27. AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Total Revenue (USD Million) (2018-2019)
Table 28. AVEO Oncology SWOT Analysis
Table 29. AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Product and Services
Table 30. AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Pfizer, Inc Basic Information, Manufacturing Base and Competitors
Table 32. Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Major Business
Table 33. Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Total Revenue (USD Million) (2018-2019)
Table 34. Pfizer, Inc SWOT Analysis
Table 35. Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Product and Services
Table 36. Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Boehringer Ingelheim International Basic Information, Manufacturing Base and Competitors
Table 38. Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Major Business
Table 39. Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Total Revenue (USD Million) (2018-2019)
Table 40. Boehringer Ingelheim International SWOT Analysis
Table 41. Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Product and Services
Table 42. Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 44. Novartis AG Neuroendocrine Tumors (NETs) Treatment Major Business
Table 45. Novartis AG Neuroendocrine Tumors (NETs) Treatment Total Revenue (USD Million) (2018-2019)
Table 46. Novartis AG SWOT Analysis
Table 47. Novartis AG Neuroendocrine Tumors (NETs) Treatment Product and Services
Table 48. Novartis AG Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. IpsenPharma Basic Information, Manufacturing Base and Competitors
Table 50. IpsenPharma Neuroendocrine Tumors (NETs) Treatment Major Business
Table 51. IpsenPharma Neuroendocrine Tumors (NETs) Treatment Total Revenue (USD Million) (2018-2019)
Table 52. IpsenPharma SWOT Analysis
Table 53. IpsenPharma Neuroendocrine Tumors (NETs) Treatment Product and Services
Table 54. IpsenPharma Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Global Neuroendocrine Tumors (NETs) Treatment Sales by Manufacturer (2018-2019) (K Pcs)
Table 56. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Manufacturer (2018-2019) (USD Million)
Table 57. Global Neuroendocrine Tumors (NETs) Treatment Sales by Regions (2015-2020) (K Pcs)
Table 58. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Regions (2015-2020)
Table 59. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Regions (2015-2020) (USD Million)
Table 60. North America Neuroendocrine Tumors (NETs) Treatment Sales by Countries (2015-2020) (K Pcs)
Table 61. North America Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Countries (2015-2020)
Table 62. North America Neuroendocrine Tumors (NETs) Treatment Revenue by Countries (2015-2020) (USD Million)
Table 63. North America Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Countries (2015-2020)
Table 64. Europe Neuroendocrine Tumors (NETs) Treatment Sales by Countries (2015-2020) (K Pcs)
Table 65. Europe Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Countries (2015-2020)
Table 66. Europe Neuroendocrine Tumors (NETs) Treatment Revenue by Countries (2015-2020) (USD Million)
Table 67. Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Sales by Regions (2015-2020) (K Pcs)
Table 68. Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Regions (2015-2020)
Table 69. Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Revenue by Regions (2015-2020) (USD Million)
Table 70. South America Neuroendocrine Tumors (NETs) Treatment Sales by Countries (2015-2020) (K Pcs)
Table 71. South America Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Countries (2015-2020)
Table 72. South America Neuroendocrine Tumors (NETs) Treatment Revenue by Countries (2015-2020) (USD Million)
Table 73. South America Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Countries (2015-2020)
Table 74. Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Sales by Countries (2015-2020) (K Pcs)
Table 75. Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Countries (2015-2020)
Table 76. Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Revenue by Countries (2015-2020) (USD Million)
Table 77. Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Countries (2015-2020)
Table 78. Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2015-2020) (K Pcs)
Table 79. Global Neuroendocrine Tumors (NETs) Treatment Sales Share by Type (2015-2020)
Table 80. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2015-2020) (USD Million)
Table 81. Global Neuroendocrine Tumors (NETs) Treatment Revenue Share by Type (2015-2020)
Table 82. Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2015-2020) (K Pcs)
Table 83. Global Neuroendocrine Tumors (NETs) Treatment Sales Share by Application (2015-2020)
Table 84. Global Neuroendocrine Tumors (NETs) Treatment Sales Forecast by Regions (2021-2025) (K Pcs)
Table 85. Global Neuroendocrine Tumors (NETs) Treatment Market Share Forecast by Regions (2021-2025)
Table 86. Global Neuroendocrine Tumors (NETs) Treatment Sales Forecast by Type (2021-2025) (K Pcs)
Table 87. Global Neuroendocrine Tumors (NETs) Treatment Market Share Forecast by Type (2021-2025)
Table 88. Global Neuroendocrine Tumors (NETs) Treatment Sales Forecast by Application (2021-2025)
Table 89. Global Neuroendocrine Tumors (NETs) Treatment Market Share Forecast by Application (2021-2025)
Table 90. Direct Channel Pros & Cons
Table 91. Indirect Channel Pros & Cons
Table 92. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Neuroendocrine Tumors (NETs) Treatment Picture
Figure 2. Global Sales Market Share of Neuroendocrine Tumors (NETs) Treatment by Type in 2019
Figure 3. Somatostatin Analogs (SSAs) Picture
Figure 4. Targeted Therapy Picture
Figure 5. Other Picture
Figure 6. Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application in 2018
Figure 7. Hospitals Picture
Figure 8. Clinics Picture
Figure 9. Other Picture
Figure 10. Global Neuroendocrine Tumors (NETs) Treatment Market Status and Outlook (2015-2025) (USD Million)
Figure 11. United States Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Canada Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Mexico Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Germany Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 15. France Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 16. UK Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Russia Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Italy Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 19. China Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Japan Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Korea Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 22. India Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Southeast Asia Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Australia Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 25. Brazil Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Egypt Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Saudi Arabia Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 28. South Africa Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Turkey Neuroendocrine Tumors (NETs) Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Manufacturer in 2019
Figure 31. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Manufacturer in 2019
Figure 32. Top 3 Neuroendocrine Tumors (NETs) Treatment Manufacturer (Revenue) Market Share in 2019
Figure 33. Top 6 Neuroendocrine Tumors (NETs) Treatment Manufacturer (Revenue) Market Share in 2019
Figure 34. Key Manufacturer Market Share Trend
Figure 35. Global Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 36. Global Neuroendocrine Tumors (NETs) Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 37. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Regions (2015-2020)
Figure 38. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Regions in 2018
Figure 39. North America Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
Figure 40. Europe Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
Figure 42. South America Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
Figure 43. Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020)
Figure 44. North America Neuroendocrine Tumors (NETs) Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 45. North America Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Countries (2015-2020)
Figure 46. North America Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Countries in 2018
Figure 47. North America Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 48. North America Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Countries in 2018
Figure 49. United States Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 50. Canada Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 51. Mexico Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 52. Europe Neuroendocrine Tumors (NETs) Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 53. Europe Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Countries (2015-2020)
Figure 54. Europe Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Countries in 2019
Figure 55. Germany Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 56. UK Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 57. France Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 58. Russia Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 59. Italy Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 60. Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 61. Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Regions 2019
Figure 62. Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Regions 2019
Figure 63. China Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 64. Japan Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 65. Korea Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 66. India Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 67. Southeast Asia Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 68. South America Neuroendocrine Tumors (NETs) Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 69. South America Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Countries in 2019
Figure 70. South America Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Countries in 2019
Figure 71. Brazil Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 72. Argentina Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 73. Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 74. Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Countries in 2019
Figure 75. Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Countries (2015-2020)
Figure 76. Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Countries in 2019
Figure 77. Saudi Arabia Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 78. Egypt Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 79. Turkey Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 80. South Africa Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 81. Global Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2025) (K Pcs)
Figure 82. Global Neuroendocrine Tumors (NETs) Treatment Revenue and Growth Rate (2021-2025) (USD Million)
Figure 83. North America Sales Neuroendocrine Tumors (NETs) Treatment Market Forecast (2021-2025) (K Pcs)
Figure 84. Europe Sales Neuroendocrine Tumors (NETs) Treatment Market Forecast (2021-2025) (K Pcs)
Figure 85. Asia-Pacific Sales Neuroendocrine Tumors (NETs) Treatment Market Forecast (2021-2025) (K Pcs)
Figure 86. South America Sales Neuroendocrine Tumors (NETs) Treatment Market Forecast (2021-2025) (K Pcs)
Figure 87. Middle East & Africa Sales Neuroendocrine Tumors (NETs) Treatment Market Forecast (2021-2025) (K Pcs)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel
神経内分泌がんの世界市場 2020年 Market Overview The global Neuroendocrine Carcinoma market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Neuroendocrine Carci…- 神経内分泌腫瘍治療薬の世界市場 2020年 Market Overview The global Neuroendocrine Tumor Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Neuroendocrine Tumo…
- 固形腫瘍における細胞分離及び特性評価の世界市場 2020年 Market Overview The global Cell Separation and Characterization in Solid Tumors market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 20…
- ソマトスタチン受容体4型の世界市場 2020年 Market Overview The global Somatostatin Receptor Type 4 market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Somatostatin Rec…
- 漁網・養殖ケージの世界市場 2020年 Market Overview The Fishing Nets and Aquaculture Cages market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain …